Sanofi says Nuvaxovid shows better tolerability than Moderna mNEXSPIKE in Phase 4 trial
PUBT · 14h ago
Share
Listen to the news
- Sanofi disclosed Phase 4 COMPARE trial results already presented at ESCMID Global Congress in Munich.
- Head-to-head study found protein-based Nuvaxovid produced fewer, less severe side effects than Moderna’s mNEXSPIKE in adults.
- Trial also showed fewer participants reported side effects that interfered with normal daily activities following Nuvaxovid vaccination.
- Patient-reported feedback indicated greater willingness to choose Nuvaxovid again for a future seasonal COVID-19 shot.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604180600PRIMZONEFULLFEED1001176496) on April 18, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved